All News

Found 128 articles

• Recce Signs Phase I Clinical Trial Agreement to Initiate Study of Synthetic Antibiotic RECCE® 327 in Healthy Subjects

  4/8/2020

  Highlights: Phase I trial agreement with leading clinical research organization Human safety and tolerability study to assess infusion of RECCE ® 327 in 40 healthy subjects as a single ascending dose   Estimated start-to-completion with data read-outs less than 12 months from now First patients expected to be dosed in second half of 2020

• Recce Pharmaceuticals Releases White Paper Providing Data and Market Positioning of its Synthetic Polymer Antibiotics

  10/23/2019

  Recce Pharmaceuticals Ltd published a white paper providing pre-clinical and experimental data on its new synthetic antibiotics and outlining the market need, its anticipated market positioning and development strategy.

• Recce Completes Raising of AU$6.76 million

  10/10/2019

  Sydney, Australia, 10 October 2019: Recce Pharmaceuticals Ltd, developing a new class of synthetic antibiotics, is pleased to announce it has raised AU$6,768,444.28 in a placement to institutional, professional and sophisticated investors that will result in 26,032,478 fully paid ordinary shares being issued at AU$0.26 per share

• Key Family 2 Patent Granted in Japan for RECCE® Antibiotics

  9/23/2019

  This second patent family, titled ‘Copolymer for use in a method of treatment of a parenteral infection’, contains 13 claims and relates to methods of manufacture, administration and application to treat a broad range of common human infections, providing Recce intellectual property protection to November 2035

• AU$5m Federal Government Grant for University and Industry Collaboration with Recce Pharmaceuticals

  8/30/2019

  Recce Pharmaceuticals Ltd announced a successful grant application as one of five Industrial Partners in collaboration with 16 University and Public Health Organisations, to establish a National Anti-Microbial Resistant Research Hub in Sydney, Australia to combat antimicrobial resistance.

• FDA Positive Response for Recce Scaled Manufacture and Quality

  8/26/2019

  Recce Pharmaceuticals Ltd announced advances in scaled manufacture and drug quality following positive Food and Drug Administration feedback to its Chemistry, Manufacturing, and Controls data pack.

• Key Family 2 Patent Granted in Europe for RECCE® Antibiotics

  8/8/2019

  Recce Pharmaceuticals Limited announced the European Patent Office has granted its patent applications for wholly owned RECCE® antibiotics, including lead compound RECCE® 327 furthering marketing/manufacturing monopolies and expanding clinical indications.

• Recce to Give Opening R&D Address at 2019 World Antibiotic Resistance Congress

  8/1/2019

  Dr John Prendergast will showcase the potential of New Synthetic Antibiotics

• Recce Board Changes - Appointment of Independent Chair and Additional Director

  7/9/2019

  Recce Pharmaceuticals Ltd, the company developing a new class of synthetic antibiotics, announced that Dr John Prendergast has been appointed to Independent Chair with founder Dr Graham Melrose stepping back from the role of Executive Chair to Executive Director and Chief Research Officer.

• RECCE PHARMACEUTICALS LTD: Leading Physician to Chair Clinical Advisory Committee

  6/6/2019

  Recce Pharmaceuticals Ltd (ASX: RCE) (Company), the company developing a new class of synthetic antibiotics, today announced the formation of a Clinical Advisory Committee to assist in the Board’s growing clinical considerations under the Therapeutic Goods Administration (TGA) Special Access Scheme (SAS).

• USA Patent Granted for Recce's Antibiotics

  3/14/2019

  Recce Pharmaceuticals Ltd (ASX:RCE) (Recce or the Company), the Company developing a new class of broad spectrum synthetic antibiotics, today announced the US Patents and Trademarks Office had Granted 23 claims for patent US 10,226,482 B2, ‘Copolymer and Method for Treatment of Bacterial Infection’.

• Recce Successfully Raises AUD$1.8 million to Advance Lead Antibiotic Program

  2/18/2019

  Recce Pharmaceuticals Ltd (ASX: RCE) (Recce or the Company), is pleased to announce that it has raised approximately AUD$1.8m (before costs) from sophisticated and institutional investors that will result in 12,857,143 fully paid ordinary shares being issued at AUD$0.14 per share (Placement).

• Recce Meets Antibiotic Leaders to Explore Commercial and Clinical Opportunities

  10/26/2018

  Reece will be represented at the World Anti-Microbial Resistance Congress in Washington D.C., 25 - 26 October 2018.

• Key Australian Patent for Recce’s Broad-Spectrum Antibiotics

  7/31/2018

  Recce Pharmaceuticals Ltd (ASX:RCE) (Company), the Company developing a new class of broad spectrum synthetic antibiotics, today announced that Australian patent WO2016/077879 ‘Copolymer and Method for Treatment of Bacterial Infection’, has been accepted for grant by the Australian Patent Office.

• Update on Progress of Broad Spectrum Antibiotic RECCE®327 Towards Clinical Trials

  7/17/2018

  Recce Pharmaceuticals Ltd today provided an update on its progress towards the start of human trials of its lead compound RECCE®327, for the treatment of sepsis, including a simple clinical trial design.

• Recce Pharmaceuticals Ltd Data Submission & Further Communication Request With Us FDA

  2/15/2018

  Recce Pharma today announced it has submitted additional data to the FDA, including an additional communication request.

• AusIndustry Awards Recce Support for AU$5.6m of Technically Advanced Overseas Drug Development

  1/15/2018

  The funds include and cover some expenditure already undertaken and apply to all antibiotics under development.

• Recce Ltd. U.S. FDA Grants Qualified Infectious Disease Product Designation for RECCE 327

  11/16/2017

  This designation is an important achievement in the regulatory path for RECCE 327 with the FDA and has significant benefits to the business.

• Recce Confirms Pre-IND Data Submission To U.S. FDA For Its Lead Antibiotic Candidate

  9/7/2017

• Recce Confirms Delivery By Intravenous Drip For Its RECCE 327 Antibiotic, With FDA IND Submission On Track

  7/31/2017